Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 immune challenge skin reaction study of SAR445399, canakinumab, and spesolimab versus placebo in healthy adults
NL-OMON60036Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of SAR445399, canakinumab and spesolimab (4 arms), sponsored by Sanofi. Started Jul 2024; status: completed.
02
Drugs
SAR445399canakinumabspesolimab
Beyond the preview
Go deeper on NL-OMON60036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60036.